Andere Sprachen Lumosa Therapeutics Co., Ltd.

Aktien

6535

TW0006535008

6535

Schlusskurs Taipei Exchange Andere Börsenplätze 00:00:00 16.05.2024			% 5 Tage	% 1. Jan.
183.5 ^TWD	0.00%		+0.55%	+168.67%

14.05.	Lumosa Therapeutics Co., Ltd. kündigt den Wechsel des Vorstandsvorsitzenden an	CI
14.05.	Lumosa Therapeutics Co., Ltd. kündigt den Wechsel des Vertreters der juristischen Person im Vorstand an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson	14.05.
Lumosa Therapeutics Co., Ltd. Announces the Change in Juristic-Person Director Representative	14.05.
Lumosa Therapeutics Co., Ltd. announced that it expects to receive TWD 50 million in funding	14.05.
Lumosa Therapeutics Co., Ltd. cancelled the transaction announced on May 31, 2023	24.04.
GenEditBio Limited announced that it has received funding from Lumosa Therapeutics Co., Ltd., Qiming Weichuang Venture Capital Management Company Limited, Innovation & Technology Fund Company, Hong Kong Science and Technology Parks, Investment Arm	07.04.
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke	02.02.
Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001	22.01.
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10.11.
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection	09.11.
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09.08.23
Lumosa Therapeutics Co., Ltd. Approves Formulation Patent for Lumosas Lt3001, A New Drug for Acute Ischemic Stroke	26.07.23
Lumosa Therapeutics Co., Ltd. Appoints Hsin-Jung Lin as Member of the Audit Committee	31.05.23
Lumosa Therapeutics Co., Ltd. Announces Appointment of Hsin-Jung Lin as Independent Director	31.05.23
Lumosa Therapeutics Co., Ltd. announced a financing transaction	31.05.23
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15.05.23
Lumosa Therapeutics Co., Ltd. Appoints Lanying Huang as Corporate Governance Officer	12.05.23
Lumosa Therapeutics Co., Ltd. announced a financing transaction	10.03.23
Lumosa Therapeutics Co., Ltd. Approves Exclusive Licensing Agreement with Pakistan’s AJM Pharma Pvt. Ltd. for LT1001, A Long-Acting Analgesic Injection	23.12.22
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10.11.22

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Lumosa Therapeutics Co., Ltd.

Aktien

6535

TW0006535008

6535

Andere Sprachen

Filter